A European pharmacotherapeutic agent roflumilast exploring integrated preclinical and clinical evidence for SARS CoV-2 mediated inflammation to organ damage

Yogendra Singh1 | Neeraj Kumar Fuloria2 | Shivkanya Fuloria2 | Vetriselvan Subramaniyan3 | Waleed Hassan Almalki4 | Fahad A. Al-abbasi5 | Imran Kazmi5 | Sobhit Singh Rajput6 | Nirmal Joshi7 | Gaurav Gupta8,9

1Department of Pharmacology, Maharishi Arvind College of Pharmacy, Jaipur, India
2Faculty of Pharmacy, AIMST University, Bedong, Malaysia
3Faculty of Medicine, Bioscience and Nursing, MAHSA University, Jenjarom, Selangor, Malaysia
4Department of Pharmacology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia
5Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia
6Aligarh College of Pharmacy, Aligarh, India
7Amrapali Institute of Pharmacy and Sciences, Haldwani, India
8Department of Pharmacology, School of Pharmacy, Suresh Gyan Vihar University, Jaipur, India
9Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India

Correspondence
Yogendra Singh, Department of Pharmacology, Maharishi Arvind College of Pharmacy, Ambabari Circle, Ambabari, Jaipur, 302023, India.
Email: yogendra.singh119@gmail.com
Gaurav Gupta, Department of Pharmacology, School of Pharmacy, Suresh Gyan Vihar University, Mahal Road, Jagatpura, Jaipur, India.
Email: gauravpharma25@gmail.com

COVID-19 has spread globally, affecting almost 160 million individuals. Elderly and pre-existing patients (such as diabetes, heart disease and asthma) seem more susceptible to severe illness with COVID-19. Roflumilast was licensed for usage in the European Union in July 2010 as a phosphodiesterase-4 (PDE4) inhibitor. Under preclinical studies, roflumilast has been shown to decrease bleomycin-induced lung fibrosis, lung hydroxyproline and right heart thickening. The current study reviewed existing data that the PDE-4 inhibitor, a roflumilast, protects renal tissues and other major organ systems after COVID-19 infection by decreasing immune cell infiltration. These immune-balancing effects of roflumilast were related to a decrease in oxidative and inflammatory burden, caspase-3 suppression and increased protein kinase A (PKA)/cyclic A.M.P. (cAMP) levels in renal and other organ tissue.

KEYWORDS
COVID-19, kidney injury, PDE-4 inhibitor, Roflumilast, tumour necrosis factor-alpha

1 INTRODUCTION

COVID-19 has spread worldwide, causing about 332 001 132 verified cases and 5 565 957 deaths in people. COVID-19 appears to be particularly dangerous to the elderly and those with pre-existing conditions (such as diabetes, cardiovascular diseases and asthma). Diabetic patients who become infected might be challenging to treat due to increases in blood glucose and other diabetes-related problems. Significant comorbidity towards SARS CoV-2-related COVID-19 includes inflammatory cytokine storm, acute kidney injury, myocardiitis, thrombosis, acute respiratory distress syndrome (ARDS) and transient ischaemic attack (T.I.A.) mediated cerebral complication that ultimately leads
to multi-organ failure. A new case report depicts a middle-aged man’s unique initial presentation and subsequent problems. The person complained of abdominal discomfort and vomiting then was diagnosed with severe acute renal damage. The study participant had a myocardial infarction and respiratory failure while in the hospital. This indicates that this patient most likely developed cardioenal syndrome due to COVID-19-associated acute renal injury.\textsuperscript{1} Notably, the main contributor to the aforementioned consequences of organ damage and death is inflammation.

Proinflammatory cytokines including as interferon-\gamma (IFN-\gamma), interleukin (I.L)-1/2/6/8 and tumour necrosis factor (TNF-\alpha), which circulate early in the SARS CoV-2 assault, directly worsen the damage by recruiting diverse leukocyte populations to the site of injury, culminating in a severe inflammatory pathway. As a result of this overexcitation, immune cells, including natural and acquired host defence systems, become overloaded, releasing more proinflammatory cytokines that accumulate or are cleared from the glomerulus, causing damage to tubular nephron segments metabolic dysregulation mediated by epithelial cell death.\textsuperscript{2,3} Furthermore, in laboratory experiments, leukocyte-platelet (P.L.T.) function has been proven to be integral to leukocyte recruitment\textsuperscript{4} and the progression of the vascular inflammation and thrombosis.\textsuperscript{5} Systemic inflammation is connected to a ‘procoagulant’ state in COVID-19 infection, characterized by overly increased tissue factor and factor VIIa levels. These findings imply that the prothrombotic activity of circulating leukocytes may contribute to the elevated cardiac, cerebral and renal vascular risk observed in individuals infected with COVID-19.\textsuperscript{6} In the early stage of the SARS CoV-2 assault, hyperinflammation and activation of the immune system, together with oxidation load lead to various pathological changes in renal tissue, including cell proliferation, podocyte (proteinuria), deposition of E.C.M. (extracellular matrix), pro-apoptotic factor activation. While the immunosuppression found in the late phase of COVID-19 disease/drug (steroids) associated impairs the body’s defences, aggravating organ damage.\textsuperscript{7} Furthermore, the peripheral blood count of monocytes and neutrophils in SARS CoV-2 patients implies immune system dysregulation at the late COVID 19 stage. In addition, the peripheral blood count in SARS CoV-2 patients for monocytes and neutrophils in this comparable time frame suggests immune system dysregulation at the late COVID 19 stage.\textsuperscript{8} Additionally, aberrant blood neutrophil motility and an increased concentration of plasma leukocytes (CD10 and CD16, for example) both suggest an increased risk of death.\textsuperscript{8,9}

Roflumilast was licensed for usage in the European Union in July 2010 as a PDE4 inhibitor. Roflumilast has been approved as a ‘congest’ treatment to bronchodilators by the E.M.A. sumamry and, under the GOLD guidelines, an effect also exists in patients not controlled on the combination of Fixed-Dose LABAs like formoterol and I.C.S. such as beclomethasone diphionate. Moreover, roflumilast coadministration with budesonide in Asians and Caucasians did not affect the steady disposition of either drug and had no consequences for its safety or tolerability, denoting that it may be consumed without or with a meal.\textsuperscript{10} However, roflumilast cessation might be because of the relatively costly medicine and, after complex prescription procedures or unpleasant effects, poor understanding of roflumilast indications between the clinicians.\textsuperscript{11} A recent study found that roflumilast protects against the functional consequences of cerebral ischemia, which might be linked to its anti-inflammatory properties.\textsuperscript{12} Another research also shows in particular that roflumilast inhibitor of PDE-4 prevents L.P.S. from releasing nitric oxide (NO), IL-1\beta, TNF-\alpha from the production of the macrophage through suppression of activation of stress-activated protein kinases (SAPK)/c-Jun N-terminal kinases (J.N.K.), p38 mitogen-activated protein kinase (MAPK), nuclear factor-kappa B (NF-\kappa B) mechanisms.\textsuperscript{13} Roflumilast has been proven in animal preventative and curative studies to reduce bleomycin-induced lung fibrosis, lung hydroxyproline and right heart thickening; it has also been shown to prevent intracoronary pulmonary artery muscularization. The inhibitor PDE4 was utilized in the bronchoalveolar lavage fluid to diminish bleomycin-induced transcripts for TNF-\alpha, transforming growth factor-beta (TGF-\beta), connective tissue growth factor synthesis, endothelin-1, al(l)collagen and mucin Muc5ac in the lung, as well as to decrease the levels of IL-13, TNF-\alpha and TGF-\beta. Moreover, lung fibrosis, al(l)collagen, right heart thickness generated by bleomycin have been reduced with roflumilast, but not dexamethasone group.\textsuperscript{14} Additionally, another study found that roflumilast and roflumilast N-oxide suppressed the release of macrophages like cell attracting molecules and TNF-\alpha release in the lungs.\textsuperscript{15}

Inflammation and immunological response are strongly related to increased PDE-4 synthesis. There are five major PDE-4 isoforms. They are PDED-4A, PDED-4B, PDED-4C, PDED-4D and PDED-4E. PDE-4B is highly upregulated on neutrophils and monocytes, resulting in the discharge of many inflammation-inducing agents.\textsuperscript{16} In contrast to earlier experimental findings, where L.P.S. injection was shown to stimulate TNF production from circulating leukocytes in PDE-4B knockout mice, it appears that this detrimental transcript effect in inflammatory conditions has been completely inhibited.\textsuperscript{17} Additionally, suppression of PDE-4B repressed apoptotic cell death and inflammation molecule biosynthesis in the renal tubular epithelial cell when treated with cisplatin. Previously, when ovalbumin was given to rats’ bronchiolar lavage fluid, PDE-4B/D expression was shown to stimulate TNF production from circulating leukocytes and macrophages like cell attracting molecules and TNF-\alpha release in the lungs.\textsuperscript{18} This study also showed a significant difference in the levels of PDE-4B transcript expression between the control group and the roflumilast group. The higher expression of these isoforms was noted in only the lavage fluid of rats with ovalbumin exposure.

However, the overexpression of PDE-4B only helped rescue allergic symptoms in this study.\textsuperscript{18} The high-dose Roflumilast significantly reduced PDE-4B/D transcripts, suggesting key involvement of these two isoforms in ARDS linked with COVID-19. These data further indicate that inhibitions of both transcripts are adequate to raise cAMP levels in renal tissue that have a protective impact on the kidney. In addition, pre-treatment dosage of Roflumilast additively decreased renal oxidative stress, inflammatory cytokines and renal tissue M.P.O. expression. The M.P.O. neutrophil enzyme is strongly prooxidizing and proinflammatory.\textsuperscript{19} Thus, roflumilast’s anti-inflammatory and anti-oxidative actions in COVID-19 infection-induced acute renal damage might be attributable to neutrophil recruitment and migratory restriction.
Additionally, research indicates that roflumilast may be helpful in atherothrombotic disorders and inflammatory vasculitis that is not primarily associated with lung damage. Notably, Roflumilast was found to improve glucose uptake and insulin sensitivity. This was linked with stimulation of the PKA/cAMP/CREB axis, which leads to PCG-1-dependent activation of mitochondrial energy production. Figure 1 Depicts the Possible Role of Roflumilast in SARS CoV-2 Mediated Inflammation to Organ Damage.

The current study reviewed existing data that the PDE-4 inhibitor protects renal tissues and other major organ systems after COVID-19 infection by decreasing immune cell infiltration. These immune-balancing effects of roflumilast were related to a decrease in oxidative and inflammatory burden, caspase-3 suppression and increased PKA/cAMP levels in renal and other organ tissue. The findings provide new information on the late-phase processes linked to COVID-19-related inflammation and the mechanisms behind roflumilast's organ-protective actions.

ACKNOWLEDGEMENT
There was no specific funding for this study.

COMPETING INTERESTS
The authors declare no competing interest.

AUTHOR CONTRIBUTIONS
Y.S., N.K.F. and S.F. proposed the study; V.S. and W.H.A. participated in all essential intellectual content sections of the study; F.A.A., I.K. and N.J. prepared figures; S.S.R. and G.G. proofread the whole manuscript. All authors approved the content of the manuscript.

DATA AVAILABILITY STATEMENT
No datasets were generated or analysed during the current study.

ORCID
Yogendra Singh https://orcid.org/0000-0001-6132-5106

REFERENCES
1. Daniels NF, Ridwan R. Acute kidney injury precipitating myocardial injury in a young male with COVID-19. Intern Med J. 2021;51(5):816-817. doi: 10.1111/imj.14977
2. Zarbock A, Gomez H, Kellum JA. Sepsis-induced acute kidney injury revisited: pathophysiology, prevention and future therapies. Curr Opin Crit Care. 2014;20(6):588-595. doi: 10.1097/MCC.0000000000000153
3. de Pablo R, Monserrat J, Prieto A, Alvarez-Mon M. Role of circulating lymphocytes in patients with sepsis. Biomed Res Int. 2014;2014, 671087. doi: 10.1155/2014/671087
4. Smyth SS, Reis ED, Zhang W, Fallon JT, Gordon RE, Coller BS. Beta (3)-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury; correlation with leukocyte recruitment to adherent platelets 1 hour after injury. Circulation. 2001;103(20):2501-2507. doi: 10.1161/01.cir.103.20.2501
5. von Brühl ML, Stark K, Steinhardt A, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012;209(4):819-835. doi: 10.1084/jem.20112322
6. McFadyen JD, Stevens H, Peter K. The emerging threat of (micro) thrombosis in COVID-19 and its therapeutic implications. Circ Res. 2020;127(4):571-587. doi: 10.1161/CIRCRESAHA.120.317447
7. Tay MZ, Poh CM, Rênia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363-374. doi: 10.1038/s41577-020-0311-8
8. Reusch N, de Domenico E, Bonaguro L, et al. Neutrophils in COVID-19. Front Immunol. 2021;12(952). doi: 10.3389/fimmu.2021.652470

FIGURE 1 Depicts the possible role of roflumilast in SARS CoV-2 mediated inflammation to organ damage.
9. Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020;26(6):842-844. doi:10.1038/s41591-020-0901-9

10. Hermann R, Siegmund W, Giessmann T, et al. The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide. J Clin Pharmacol. 2007;47(8):1005-1013. doi:10.1177/0091270007300950

11. Salvesen ØNU, Davidsen JR, Pottegård A, Henriksen DP. Roflumilast usage from 2010 to 2016: a Danish Nationwide Drug Utilization Study. Basic Clin Pharmacol Toxicol. 2018;123(3):314-319. doi:10.1111/bcpt.13014

12. Bonato JM, Meyer E, de Mendonça PSB, Milani H, Prickaerts J, Weffort de Oliveira RM. Roflumilast protects against spatial memory impairments and exerts anti-inflammatory effects after transient global cerebral ischemia. Eur J Neurosci. 2021;53(4):1171-1188. doi:10.1111/ejn.15089

13. Kwak HJ, Song JS, Heo JY, Yang SD, Nam JY, Cheon HG. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J Pharmacol Exp Ther. 2005;315(3):1188-1195. doi:10.1124/jpet.105.092056

14. Cortijo J, Iranzo A, Milara X, et al. Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury. Br J Pharmacol. 2009;156(3):534-544. doi:10.1111/j.1476-5381.2008.00411.x

15. Buenestado A, Grassin-Delyle S, Guittard F, et al. Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide. Br J Pharmacol. 2012;165(6):1877-1890. doi:10.1111/j.1476-5381.2011.01667.x

16. Wang P, Wu P, Ohleth KM, Egan RW, Billah MM. Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol. 1999;56(1):170-174. doi:10.1124/mol.56.1.170

17. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A. 2002;99(11):7628-7633. doi:10.1073/pnas.122041599

18. Zheng XY, Chen JC, Xie QM, Chen JQ, Tang HF. Anti-inflammatory effect of ciclamilast in an allergic model involving the expression of PDE4B. Mol Med Rep. 2019;19(3):1728-1738. doi:10.3892/mmr.2019.9802

19. Souto FO, Alves-Filho JC, Turato WM, Auxiliadora-Martins M, Basile-Filho A, Cunha FQ. Essential role of CCR2 in neutrophil tissue infiltration and multiple organ dysfunction in sepsis. Am J Respir Crit Care Med. 2011;183(2):234-242. doi:10.1164/rccm.201003-0416OC

20. Totani L, Amore C, di Santo A, et al. Roflumilast inhibits leukocyte–platelet interactions and prevents the prothrombotic functions of polymorphonuclear leukocytes and monocytes. J Thromb Haemost. 2016;14(1):191-204. doi:10.1111/jth.13173

How to cite this article: Singh Y, Fuloria NK, Fuloria S, et al. A European pharmacotherapeutic agent roflumilast exploring integrated preclinical and clinical evidence for SARS CoV-2 mediated inflammation to organ damage. Br J Clin Pharmacol. 2022;88(8):3562-3565. doi:10.1111/bcp.15328